EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ebanga™: The most recent FDA-approved drug for treating Ebola

Elahe Taki, Roya Ghanavati, Tahereh Navidifar, Shirin Dashtbin, Mohsen Heidary, Marjan Moghadamnia

Frontiers in Pharmacology · 08.03.2023 · 14

DOI: 10.3389/fphar.2023.1083429 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.03.2023. Verfasst von Elahe Taki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ebolavirus (EBOV) is a virulent pathogen that causes Ebola virus disease (EVD), which is a life-threatening human condition with a fatality rate of up to 90%. Since the first outbreak in Africa in 1976, several outbreaks and epidemics of EBOV have occurred across the globe. While EVD is recognized as a serious threat to human health and outbreaks occur almost every year, the treatment options for the disease are limited. In designing therapeutic strategies against EBOV infection, viral structural proteins, such as glycoprotein (GP), could be an excellent target for neutralizing the virus. According to the latest research, GP-specific antibodies are the most efficient post-exposure treatments for EVD. Ansuvimab-zykl, i.e., mAb114 (Ebanga™), is a recent FDA-approved human immunoglobulin monoclonal antibody targeting EBOV GP. This review provides a brief overview of the pharmacological effects and safety profile of ansuvimab in clinical trials and provides insights into the precise mechanism of this new drug for treating EVD.

Schlagwörter

Stichwörter der Autor:innen

EbangaTMEbola virusansuvimab-zyklmAb114monoclonal antibodytreatment

Autor:innen und Institutionen

  • Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Behbahan Faculty of Medical Sciences, Behbahan, Iran.
  • Department of Basic Sciences, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran.
  • Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran.

Zitieren

APA

Taki, E., Ghanavati, R., Navidifar, T., Dashtbin, S., Heidary, M., & Moghadamnia, M. (2023). Ebanga™: The most recent FDA-approved drug for treating Ebola. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1083429

Vancouver

Taki E, Ghanavati R, Navidifar T, Dashtbin S, Heidary M, Moghadamnia M. Ebanga™: The most recent FDA-approved drug for treating Ebola. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1083429

BibTeX
@article{Taki2023,
  author = {Taki, Elahe and Ghanavati, Roya and Navidifar, Tahereh and Dashtbin, Shirin and Heidary, Mohsen and Moghadamnia, Marjan},
  title = {Ebanga™: The most recent FDA-approved drug for treating Ebola},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1083429}
}
Kostenlos starten →